VTVT vTv Therapeutics Inc.

1.31
+0.01  (+0%)
Previous Close 1.3
Open 1.29
Price To Book -0.74
Market Cap 61195104
Shares 46,713,820
Volume 100,178
Short Ratio
Av. Daily Volume 466,330

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data due June 2019.
TTP399
Type 1 Diabetes
Phase 2 data released August 2016. Primary endpoint met.
TTP399 - AGATA
Type 2 Diabetes
Phase 2 primary endpoint met - December 14, 2016.
TTP273 - LOGRA
Type 2 Diabetes
Phase 3 data both Part A (April 9, 2018) and Part B (June 12, 2018) did not meet endpoints.
Azeliragon - STEADFAST
Mild Alzheimer’s disease
Phase 2/3 enrolment to be initiated mid-2019.
Azeliragon
Mild Alzheimer’s disease with type 2 diabetes

Latest News

  1. Zacks.com featured highlights include: VALE, Second Sight, Carbonite, Arconic and vTv
  2. Get Over Bargain Hunting: Tap 5 Stocks With Rising P/E
  3. FDA Events Can Send Stocks Soaring: Here's One That No One Is Talking About
  4. vTv Therapeutics to Present at the 14th International Conference on Alzheimer’s & Parkinson’s Diseases
  5. Triad biopharmaceutical company seeks to raise $6 million
  6. vTv Therapeutics Announces $15 Million of Class A Common Stock Financings
  7. vTv Therapeutics Announces 2018 Fourth Quarter and Full Year Financial Results and Update
  8. Watch These 4 Healthcare Stocks Set the Pace on Friday (1/25/19)
  9. vTv Therapeutics Announces Publication of Comprehensive Data in Science Translational Medicine Detailing the Discovery and Clinical Development of TTP399, including Results of Phase 2 AGATA Study
  10. 10 trading lessons for 2019 that we learned from the 2018 stock market selloff
  11. Watch These Top Trending Stocks On Jan. 2, 2019
  12. Biotech Rally Ahead of the Market
  13. 4 Healthcare Stocks That Are Raising Eyebrows
  14. Biotech Companies in the News
  15. 4 Healthcare Stocks Gaining Speed on Friday (12/28/18)
  16. Detailed Research: Economic Perspectives on Honeywell International, Tabula Rasa Healthcare, El Pollo Loco, Acceleron Pharma, vTv Therapeutics, and 22nd Century Group — What Drives Growth in Today's Competitive Landscape
  17. vTv Therapeutics to Present at the 30th Annual Piper Jaffray Healthcare Conference
  18. VTv Therapeutics (VTVT) Reports Q3 Loss, Tops Revenue Estimates
  19. VTv Therapeutics: 3Q Earnings Snapshot
  20. vTv Therapeutics Announces Third Quarter 2018 Results and Update